Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation
about
sameAs
Ghostwriting at elite academic medical centers in the United StatesWhat should be done to tackle ghostwriting in the medical literature?Citability of original research and reviews in journals and their sponsored supplementsReporting bias in medical research - a narrative reviewThe haunting of medical journals: how ghostwriting sold "HRT"Industry sponsorship and research outcomePartisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy.Systematic review on the primary and secondary reporting of the prevalence of ghostwriting in the medical literatureStudy of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trialCONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trialsIntegrity in authorship and publicationConflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journalsGhostwriting: the dirty little secret of medical publishing that just got biggerProfessional medical organizations and commercial conflicts of interest: ethical issuesObesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorshipConflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort studyStrategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaintsIndustry Collaboration and Primary Guest Authorship of High-Impact Randomized Clinical Trials: A Cross-Sectional StudyPharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012Who has used internal company documents for biomedical and public health research and where did they find them?SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trialsVulnerability in clinical research with patients in pain: a risk analysis.Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?Outsourcing neuroimaging data analysis Implications for scientific accountability and issues in the public interest.The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.Editors, publishers, impact factors, and reprint incomeAuthorship ethics in global health research partnerships between researchers from low or middle income countries and high income countriesKnowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research.'Primum non nocere': A review of Taking America off Drugs: Why Behavioral Therapy is More Effective for Treating ADHD, OCD, Depression and Other Psychological Problems by Stephen Ray Flora.Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles.Integrity in scientific publishingPublic perceptions of physician - pharmaceutical industry interactions: a systematic review.Legal remedies for medical ghostwriting: imposing fraud liability on guest authors of ghostwritten articlesThose who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications.Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey.Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic reviewChallenging medical ghostwriting in US courts.Of sophists and spin-doctors: industry-sponsored ghostwriting and the crisis of academic medicine.Knowledge of undisclosed corporate authorship ("ghostwriting") reduces the perceived credibility of antidepressant research: a randomized vignette study with experienced nurses.Investigator experiences with financial conflicts of interest in clinical trials.
P2860
Q21090130-4592C00D-A1CF-4BD1-842C-6CE092D1A6A0Q21090135-ABD083E0-5698-4EE6-BC8D-DD56F2379CEEQ21091143-38B1DD3A-72C6-42F9-A894-D47DDABBAE4CQ21203744-AFB4ACE0-136A-47EF-9A68-39E5C4427BEFQ21563448-06AA8798-B795-4D50-87AB-7E5E278FBFF8Q24202591-BFEB87DD-CFD7-4D84-BFAC-26245698E400Q24289488-EFC01E92-C9D6-4289-A9FF-F9B5826F346FQ24561610-A6F25734-9537-4F33-991A-A60875AB6240Q24604806-785F1223-08A9-4326-BA42-AE1A5BE0457EQ24614627-42D7550C-02CF-4B9E-A447-77235C68CA1DQ24643950-703AB38E-5ECA-4977-81DE-99A9DA60F3CCQ24644642-0ABC8B0F-9E0B-42A1-962D-A0AC4ADD227DQ28119336-4278D57D-A1E7-4EF5-A9F2-823F17F489C8Q28288321-AE632525-C599-4519-91B5-9A5F92216DCFQ28475155-75D78C5E-BF45-4D2D-87C0-C59664C977F6Q28475928-D5D46382-CEA3-4722-98AA-85B6C566A519Q28477644-2C8FEA1E-B727-45C8-8BEA-AD72A98FCFC1Q28548347-FB2A4625-8DE5-480E-AC8D-C848DAF17EEEQ28552890-CA399149-7429-489D-B082-1C87DF3211C9Q28657906-29AA724A-AEA4-41FA-B1B8-4FDC03503373Q28710019-62345D2A-4096-4333-99D5-BDED788202CBQ30431269-580AEBBB-84C9-4120-B151-2835160B494AQ33364538-AF5AB700-FF8B-4451-9BEE-BBDA779527EDQ33511695-C4866391-E34E-44B3-89F0-25C650580D74Q33583631-5D3892C9-A740-4ECC-8989-65D17453E01FQ33737605-3B019FEC-FFC5-4054-9DEE-A1BDE06A45F7Q33772338-7E9F71C0-E392-40B6-94A1-21D4BD1A562DQ33807895-36BC8CD6-8F15-4507-953E-BC9F7CDF347CQ33811019-01F8E9FB-A2CE-4A5E-9CA3-88AD0A97C64AQ33851285-A145549A-D32F-4694-81CF-380F5B438622Q33874170-38D84CF1-5E03-431A-92ED-CF43C593970EQ33874709-EB93CF55-89B4-47E7-AE04-5F8C8DD2F447Q33987346-10D1F4E9-4BE7-44AE-BA02-A2B3469A6154Q34025773-E39213A7-11F4-433F-BAA4-8473070C78C8Q34057966-07A93836-CE43-47AE-934E-72D76A789368Q34105156-DE02AB73-0FC2-4C5D-BCE2-BD12EAD7153BQ34145613-BCB33A8A-F834-4305-99DA-25E9F1809BA6Q34165083-B7FFB3AF-149D-4822-984A-8EBB94B8A67EQ34403714-892FD344-4669-48D2-A8C2-DD633C5DD5FEQ34540824-9BA0BCE2-EAD8-4673-B56E-D843392E39E6
P2860
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Guest authorship and ghostwrit ...... ents from rofecoxib litigation
@ast
Guest authorship and ghostwrit ...... ents from rofecoxib litigation
@en
Guest authorship and ghostwrit ...... ents from rofecoxib litigation
@nl
type
label
Guest authorship and ghostwrit ...... ents from rofecoxib litigation
@ast
Guest authorship and ghostwrit ...... ents from rofecoxib litigation
@en
Guest authorship and ghostwrit ...... ents from rofecoxib litigation
@nl
altLabel
Guest Authorship and Ghostwriting in Publications Related to Rofecoxib
@en
prefLabel
Guest authorship and ghostwrit ...... ents from rofecoxib litigation
@ast
Guest authorship and ghostwrit ...... ents from rofecoxib litigation
@en
Guest authorship and ghostwrit ...... ents from rofecoxib litigation
@nl
P2093
P3181
P356
P1476
Guest Authorship and Ghostwriting in Publications Related to Rofecoxib
@en
Guest authorship and ghostwrit ...... ents from rofecoxib litigation
@en
P2093
David S Egilman
David S. Egilman
Joseph S. Ross
Kevin P Hill
Kevin P. Hill
P3181
P356
10.1001/JAMA.299.15.1800
P407
P577
2008-04-16T00:00:00Z